Kevin Krause
CEO
ArrePath
The startup operates a drug discovery platform focused on developing therapies for antimicrobial resistance by targeting multiple pathways in disease modulation. This approach enhances the efficacy of new medicines while minimizing risks during the discovery and development phases, ultimately improving treatment outcomes for chronic ailments.
- Artificial Intelligence
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$20MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
The increasing prevalence of antimicrobial resistance (AMR) poses a significant threat to global health, leading to ineffective treatments for common infections and increased mortality rates. Traditional drug discovery methods struggle to keep pace with the rapid evolution of resistant bacteria, resulting in a critical need for novel therapeutic approaches. Current R&D efforts have seen a decline, with few recent innovations and most approvals being derivatives of known classes.
Solution
ArrePath is developing novel small molecule therapeutics to combat antimicrobial resistance and address unmet medical needs in infectious and respiratory diseases. The company's AI/ML-powered drug discovery platform integrates human intelligence with multimodal data analysis to identify and optimize compounds with progressible attributes. By combining data across disparate assays and rigorously evaluating models in real-world use cases, ArrePath accelerates the discovery process and increases the likelihood of identifying novel drug candidates. The platform leverages machine learning to guide compound selection, predict mechanisms of action, and optimize multiple properties simultaneously, such as bioactivity, ADMET (absorption, distribution, metabolism, excretion, and toxicity) characteristics, and target binding. This approach enables the discovery of differentiated classes of therapeutics with novel mechanisms of action.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and healthcare providers focused on developing and utilizing novel therapeutics to combat antimicrobial resistance and treat infectious and respiratory diseases.
Features
- AI/ML platform integrating bioactivity with structure-guided and ligand-guided optimization
- Predictive ML models for antibacterial activity, cytotoxicity, and ADMET properties
- ML-enabled microscopy for rapid prediction of mechanism and mechanistic novelty
- ArrenautAI tool integrating bioactivity with structure-guided and ligand-guided optimization
- Learning-to-rank models allowing ingestion of multiple heterogeneous datasets
- Virtual and experimental compound testing to accelerate compound optimization
- Lead program targeting an unrealized mechanism of action in Gram-negative bacteria